WO1996040081A2 - Oral delivery of gene constructs - Google Patents
Oral delivery of gene constructs Download PDFInfo
- Publication number
- WO1996040081A2 WO1996040081A2 PCT/US1996/009371 US9609371W WO9640081A2 WO 1996040081 A2 WO1996040081 A2 WO 1996040081A2 US 9609371 W US9609371 W US 9609371W WO 9640081 A2 WO9640081 A2 WO 9640081A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene construct
- delivery
- gene
- formulation
- therapeutic protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 108
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 63
- 238000009472 formulation Methods 0.000 claims description 51
- 239000013598 vector Substances 0.000 claims description 21
- 238000001415 gene therapy Methods 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 13
- 239000013603 viral vector Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 230000009885 systemic effect Effects 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- -1 cationic lipid Chemical class 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 230000008488 polyadenylation Effects 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 description 45
- 239000012530 fluid Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 15
- 230000003204 osmotic effect Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 241001068295 Replication defective viruses Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 108010071397 lactoferrin receptors Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention is related to orally delivered gene therapy vectors. More particularly, it is related to oral delivery of gene constructs to a target site in the gastrointestinal tract to accomplish mucosal or systemic immunization or expression of a therapeutic protein for local or systemic use.
- Gene therapy has been suggested for treating a wide variety of genetic and acquired diseases. Somatic gene therapy has previously focused on transduction of bone marrow stem cells and lymphocytes derived from the circulation and solid tissues. Many delivery methods have been described for gene therapy including nasal, pulmonary and intra-muscular methods.
- the Gl system has been noted as advantageous as a target for gene therapy in that it is readily accessible by endoscope, it contains progenitor cells in the crypts which are immortal, and it is capable of sustained proliferation in vivo (F. Ledley, J. Pediatric Gastroenterology and Nutrition. 14:328-337(1992).
- Gene therapy can be effected in two basic ways: by in vivo delivery and by ex vivo delivery followed by return of cells to the patient (M.
- Lactoferrin is an iron binding protein that binds both to DNA and to specific receptors on target cells.
- the lactoferrin-DNA complex binds to the lactoferrin receptor in the small bowel and enters the cells by receptor mediated endocytosis.
- a lactoferrin-DNA complex thus can be used for oral gene delivery where formulated with a milk lipid micelle.
- Osmotic dispensing devices for delivery of therapeutically active agents are well known in the art. Such devices use an expansion means to deliver an agent to an environment of use over a period of hours, days or months.
- the expansion means absorbs liquid, expands, and acts to drive out beneficial agent formulation from the interior of the device in a controlled, usually constant manner.
- the osmotic expansion means is used to controllably deliver the agent, usually relatively slowly, and over a period of time.
- these devices are not generally used to delay the initial release of the agent, followed by the rapid release, or substantially simultaneous introduction, of all of the agent or all of the dosage form(s) containing the agent into the environment of use at one time (see e.g. US Patent Nos.
- US Patent No. 5,342,624 which is incorporated by reference herein, discloses an oral delivery capsule having two pieces, one of which is a plug made of a water-sensitive material.
- a delay in the initial release of an agent occurs when the plug takes up water and results in the plug swelling or expanding and eventually separating from the body of the capsule to allow release of the agent contained within.
- the swelling and eventual release of the plug causes the volume inside the capsule to expand, which creates a vacuum within the capsule that causes fluid from the fluid environment to enter the capsule and come into contact with the active agent.
- the active agent is sensitive to fluids, as are the viral and nonviral vectors useful for gene therapy, such contact can cause agglomeration or inactivation of the agent. Additionally, the fluid taken up by the swelling
- SUBSTITUTE SHEET water-sensitive plug also can come into contact with fluid-sensitive active agents.
- the invention is directed to a method for providing human gene therapy.
- the method involves oral administration of a gene construct or vector that is delivered as a bolus dose to a target site in the gastrointestinal tract.
- the present invention is also directed to a fluid-imbibing dispensing device for the delivery of a gene construct to the gastrointestinal tract for gene therapy.
- the device comprises a housing having two separable pieces.
- the first separable piece defines a water-impermeable container that contains a gene construct formulation.
- An expansion agent in the device causes separation of the pieces of the housing after exposure to the environment of use to effect delivery of the gene construct to the target site in the Gl tract.
- FIG. 1 is a cross-sectional view of one embodiment of the device of the present invention, the device being in closed or prepared form prior to placement in the environment of use.
- FIG. 2 is the device of FIG. 1 in operation after activation by placement in the environment of use, showing the device opened to release the gene construct to the environment.
- FIG. 3 is a cross-sectional view of a further embodiment of the device of the present invention, the device being in closed or prepared form prior to placement in the environment of use.
- FIG. 4 is the device of FIG. 3 in operation after activation by placement in the environment of use, showing the device opened to release the gene construct to the environment.
- the present invention is a method and device for delivering a gene construct to a targeted site in the gastrointestinal (Gl) tract. Delivery of the gene construct formulation, once begun, is quickly completed.
- the delivery device is designed to simultaneously introduce all of the gene construct formulation to a target site in the Gl tract in a bolus dose after entry of the device into the Gl tract.
- gene therapy is intended the delivery of gene constructs or vectors to a target site to accomplish mucosal or systemic immunization or expression of a therapeutic protein for local or systemic use.
- bolus dose we intend that essentially all of the gene construct formulation in a device is released in a short period of time of one hour or less and usually within 45 minutes, preferably in less than about 30 minutes.
- essentially all of the gene construct formulation is intended greater than about 85%, preferably above 95% and usually greater than 98% of the gene construct formulation contained in a device.
- terapéuticaally effective amount or “therapeutically effective rate” refer to the amount or administration rate of a gene such that the expression level results in the desired therapeutic, often beneficial result.
- therapeutic protein is intended a protein or polypeptide that provides some pharmacologic, often beneficial effect. This effect may be localized in the gastrointestinal tract or may be systemic. Examples of these agents that are useful for systemic administration include but are not limited to c* ! antitrypsin, factor VIII, factor IX and other coagulation factors, growth hormone, insulin and other peptide hormones, adrenal cortical stimulating hormone, thyroid stimulating hormone and other pituitary hormones, interferon ⁇ , ⁇ and ⁇ , erythropoietin, growth factors, tissue plasminogen activator, CD4, interleukin-1 receptor antagonist, tumor necrosis factor receptor, and recombinant antibodies and antibody fragments and the like.
- proteins are useful for the treatment of a variety of conditions including but not limited to hemophilia and other blood disorders, growth disorders, diabetes, leukemia, hepatitis, renal failure, HIV infection, hereditary diseases such as cerebrosidase deficiency and adenosine deaminase deficiency, hypertension, septic shock, autoimmune diseases such as multiple sclerosis, Graves disease, systemic lupus erythematosus and rheumatoid arthritis, shock and wasting disorders, cystic fibrosis, lactose intolerance, Crohn's diseases, inflammatory bowel disease, and gastrointestinal and other cancers.
- hereditary diseases such as cerebrosidase deficiency and adenosine deaminase deficiency
- hypertension septic shock
- autoimmune diseases such as multiple sclerosis, Graves disease, systemic lupus erythematosus and rheumatoid arthritis, shock
- a further beneficial effect may be accomplished by gene production of recombinant peptides, and oral immunization may be accomplished by gene production of recombinant viral, parasitic, bacterial or other antigens.
- impermeable is meant that the particular portion of the device is impermeable to fluids and ingredients contained in the device and in the intestinal environment.
- semipermeable is meant that the housing is permeable to fluid but impermeable to other ingredients contained in the device or in the intestinal environment.
- vector and “gene construct” are used interchangeably herein and refer to combinations of genetic elements that encode a therapeutic protein with elements that regulate the level of expression of the product.
- viral vector is intended the packaging of a recombinant gene within a viral or viral-related particle. Viral function is then used to infect and integrate the gene into the target cell. The gene will then express the therapeutic protein.
- Viral vectors that are useful in the devices of the invention include but are not limited to retroviruses, adenoviruses, adeno- associated viruses, vaccinia and herpes simplex viruses.
- nonviral vector a recombinant gene that may or may not be associated with chemical or biological compounds that stabilize or facilitate cellular uptake of the DNA.
- a recombinant DNA molecule with a promoter and polyadenylation signal is incorporated into a DNA backbone.
- Other examples include the use of cationic and neutral lipids complexed with the DNA molecules and the addition of proteins or chimeric proteins that confer receptor-mediated uptake of DNA (see eg, MA Morsy et al, JAMA. 270:19, 2338-2345 (November 17, 1993) and FD Ledley, J Pediatric Gastroenterology and Nutrition 14:328-337 (1992) which are incorporated by reference herein).
- gene construct formulation intends the viral or nonviral vector optionally in combination with pharmaceutically acceptable carriers and additional inert materials. It is to be understood that more than one type of viral or nonviral vector may be incorporated into the gene construct formulation in a device of this invention, and that the use of the term “vector” or “gene construct” in no way excludes the use of two or more such agents.
- the amount of viral or non-viral vector employed in the delivery device will be that amount necessary to cause the expression of a therapeutically effective amount of the therapeutic protein to achieve the desired result. In practice, this will vary widely depending upon the particular agent, the site of delivery, the severity of the condition, and the desired therapeutic effect. Thus, it is not practical to define a particular range for the amount of gene construct or vector incorporated into the device.
- the pharmaceutically acceptable carrier useful herein may comprise more than one ingredient, such as, for example, buffers, viscosity regulating vehicles, surfactants, dyes, permeation enhancers, proteinase inhibitors, mucolytic agents or other formulation ingredients and additives such as those that facilitate uptake of the agents by the targetted cells or that promote rapid release of the gene construct from the delivery device, as are known in the art.
- the carrier may contain more than one gene construct.
- the present invention involves delivery of a gene construct to a targeted portion of the Gl tract.
- Potential portions of the Gl tract that may be targeted include but are not limited to the distal small intestine, the M cells, the Peyer's Patches and the upper colon.
- Such targeting will promote transduction of gastrointestinal epithelial cells or M cells at the delivery site.
- devices such as those described below may be taken orally. These devices will retain the gene construct formulation such that delivery into the stomach and upper intestine will be prevented and a bolus dose will be delivered at the target site.
- FIG. 1 depicts in cross-sectional view one embodiment of a delivery device for delivering a gene construct according to the present invention.
- the device is shown in closed or prepared form prior to placement in the environment of use.
- Dispensing device 1 comprises a housing 12 formed of a first wall section 14 and a second wall section 16.
- First wall section 14 and second wall section 16 are in reversibly sliding telescopic arrangement with each other.
- Housing 12 surrounds and defines an internal compartment 18.
- First wall section 14 surrounds that portion of internal compartment 18 that contains the gene construct formulation 20.
- Second wall section 16
- SUBSTITUTE SHEET surrounds that portion of internal compartment 18 that contains an expansion agent 22 for expanding and for occupying space in compartment 18.
- Second wall section 16 also contains a piston 24 which is positioned between the agent formulation 20 and the expansion agent 22.
- Piston 24, may comprise a composition that is substantially impermeable to the passage of fluid, so that it restricts the passage of fluid present in the expansion means into that area of compartment 18 that contains the gene construct formulation. It operates to essentially maintain the integrity of the gene construct formulation and the expansion agent.
- piston 24 acts to insure that the expanding driving force generated by the expansion agent 22 is applied directly against the first wall section 14 to effect the separation of the two wall sections.
- piston 24 must be of sufficient strength, thickness and rigidity to transfer the driving force against first wall section 14.
- First wall section 14 and second wall section 16 at their open ends are close in size and they form a friction fit there between.
- the friction generated is sufficient to maintain the two wall sections together prior to activation of the expansion means but not so great as to keep the two wall sections from sliding apart once an expanding driving force is exerted.
- protrusions or other means may be present on one or the other of the contacting surfaces of the first and second wall sections.
- First wall section 14 and second wall section 16 can be telescoped completely into a closed and continuous external walled position. The open end of first wall section 14 is adapted to fit within second wall section 16.
- expansion agent 22 absorbs and imbibes fluid through second wall section 16 from the environment of use, it expands and pushes against piston 24, causing the piston to slide inside compartment 18.
- Piston 24 pushes against first wall section 14 to cause the first wall section to slide apart from second wall section 16 as the expansion agent 22 continues to expand. This causes the two wall sections to become separated and the gene construct formulation 20 to be exposed to the environment of use, as
- FIG. 2 illustrates the dispensing device 1 of FIG. 1 in operation after activation of the device by placement in the environment of use.
- FIG. 2 shows device 1 opened to release all of the gene construct formulation 20 to the environment substantially at the same time.
- First wall section 14 has been separated from second wall section 16 by the expanding driving force of the expansion agent 22, which has expanded in size as a result of imbibing fluid from the environment.
- First wall section 14 may comprise a composition that is semipermeable, that is, it is permeable to fluid but impermeable to the gene construct and other ingredients contained in dispensing device 1, or it may, alternatively, comprise a composition that is impermeable to the exchange of fluid, agent and other ingredients.
- first wall section 14 be substantially impermeable to the ingress of the external fluid to serve as a means for substantially protecting the gene construct formulation 20 until it is expelled from housing 12 and delivered into the environment of use.
- second wall section 16 in at least a portion that is adjacent to expansion agent 22 must be semipermeable; that is, it is permeable to the passage of fluid while being substantially impermeable to the passage of other ingredients contained in dispensing device 1.
- Wall sections 14 and 16 optionally comprise additional ingredients such as, for example, a plasticizer.
- Impermeable and semipermeable compositions suitable for use in wall sections 14 or 16, as well as suitable additives, are known in the art, examples of which are disclosed in U.S. Pat. 4,874,388, which is incorporated herein by reference.
- Housing 12 comprising wall sections 14 and 16 is nontoxic, biologically inert, nonallergenic and nonirritating to body tissue, and it maintains its physical and chemical integrity; that is, housing 12 does not erode or degrade in the environment of use during the dispensing period. It is within the scope of the invention that the housing be insoluble only during the period of intended use and can thereafter dissolve away in the environment of use. Thus, a dispenser is contemplated which is unaffected by its environment, solubility-wise, at the site of use or which, alternatively, is only slightly soluble during the period of intended use, such that once its contents have been removed, it will dissolve or erode away leaving no objectionable residue or empty container at the site of use.
- the expansion agent or expandable driving member 22, operable for separating the first and second wall sections to release the gene construct formulation 20 from the dispensing device of the invention, is nontoxic, nonallergenic and biologically inert.
- Expansion agent 22 comp ses, in one embodiment, an osmopolymer. Osmopolymers interact with water and aqueous biological fluids and swell or expand to ah equilibrium state. Osmopolymers exhibit the ability to swell in fluid and to retain a significant portion of the imbibed and absorbed fluid within the polymer structure.
- the expansion agent 22 in another embodiment comprises an osmagent.
- Osmagents are known also as osmotically effective solutes and compounds.
- Osmagents that can be used for the purpose of this invention include inorganic and organic compounds that exhibit an osmotic pressure gradient across a semipermeable, i.e. a fluid-permeable, wall.
- the expansion agent 22 in yet another embodiment comprises an osmagent dispersed within an
- the expansion agent 22 can comprise a tablet or a layer, or a plurality of tablets or layers, or it can be pressed into second wall section 16.
- the osmagent or osmopolymer can be in any suitable form such as particles, crystals, pellets, granules, and the like, when pressed into a tablet layer and into wall section 16.
- Osmagents and osmopolymers are known to the art and are described in, for example, U.S. Pat. Nos. 3,865,108, 4,002,173, 4,207,893, 4,327,725 and 4,612,008.
- Piston 24, present in certain embodiments of the invention between the active agent formulation and the expansion agent transmits the force generated by the expansion agent against the first wall section 14 and maintains the separate identity of the gene construct formulation and the expansion agent, and substantially restricts the passage of fluid between the gene construct formulation and the expansion agent.
- Representative materials useful as a piston 24 are known to the art in, for example, U.S. Pat. No. 4,874,388.
- FIG. 3 illustrates another embodiment of a dispensing device for delivering the a gene construct according to the present invention.
- dispensing device 30 has a housing 32 with an orifice 34 and a plug 36.
- the housing 32 has a permeable or semipermeable portion 38 that contains an expansion agent 40 and an impermeable portion 44 that contains the gene construct formulation 20.
- An impermeable piston 42 separates the expansion agent 40 and the gene construct formulation 20.
- the expansion agent 40 will begin to expand in the fluid environment, the cylindrical plug 36 and housing 32 will separate and the gene construct formulation 20 will be delivered to the target site in the Gl tract.
- PulsincapTM devices R.P. Scherer Co., Swindon, England
- the total delay time prior to separation of the dispensing device and delivery of the gene construct formulation is usually in the range of from about 1 to 24 hours, preferably between about 2 and 15 hours and often in the 4 to 8 hour range and can be controlled by a number of means.
- the rate of fluid imbibition into the expansion agent can be controlled by the particular choice of semipermeable membrane.
- the rate of expansion of the expansion agent can be controlled by the choice of composition of the expansion agent.
- the distance of overlap between the open end portions of the first and second wall sections can determine the period of time required for the two sections to separate. Combinations of such means may be used.
- Such control means are known in the art and can be determined without undue experimentation.
- PulsincapTM that comprises an impermeable capsule and a hydrogel plug.
- the plug is designed to swell and dislodge from the device after a particular time period, thereby delivering its contents in a bolus following a predetermined delay. See, e.g., European Patent No. 0384642, which is incorporated by reference herein.
- Another example of a device that will deliver a bolus dose following a particular delay is the Time-Clock® described in U.S.
- Patent No. 5,310,558 which is incorporated by reference herein.
- a core containing the active agent is coated by a hydrophobic layer.
- the hydrophobic layer is programmed to disintegrate after a particular amount of time and thereafter release the active agent.
- Other devices have been designed that release a bolus dose upon, for example, activation of a radio-frequency signal (see, e.g., U.S. Patent No. 3,894,538, incorporated by reference herein), and as a result of a heating by ultrasonic waves (see e.g., U.S. Patent No. 4,507,115, which is incorporated by reference herein).
- the bolus delivery described in the present application can be effected by the above-described drug delivery devices as well as any other devices that are now known, or hereafter developed, to have the same capabilities.
- the dispensing device For proper delivery of the gene construct, the dispensing device must deliver the gene construct formulation to a particular portion of the Gl tract. Thus, it is necessary for the device to pass through particular portions of the Gl tract to another prior to delivering the gene construct.
- an enteric coating may be applied over at least that portion of the housing of the dispensing device that is comprised of a semipermeable membrane adjacent to the fluid-activated expansion means. Enteric coatings will remain intact in the stomach but will rapidly dissolve once they arrive at the small intestine, thereafter allowing fluid to be imbibed to activate the dispensing device.
- the gene constructs may be prepared from viral or nonviral vectors.
- the formulation is prepared by generating specific constructs containing the desired genetic material. The replication region of the viral genome is deleted and replaced with a therapeutic gene. The replication-defective virus is then propagated, recovered after cell lysis, purified and then concentrated.
- the formulation may include the therapeutic gene alone or the gene may be incorporated, for example, into a liposome or a cationic lipid complex.
- Possible semipermeable materials from which the second housing 16 may be prepared include, for example, water flux enhanced Hytrel® polyester elastomers (Du Pont), cellulose esters, water flux enhanced ethylene-vinyl acetate copolymers, semipermeable membranes made by blending a rigid polymer with water-soluble low molecular weight compounds, and other semipermeable materials known in the art.
- Impermeable materials from which the first housing 14 may be prepared include, for example, polyethylene, polystyrene, ethylene-vinyl acetate copolymers, Hytrel® polyester elastomers (Du Pont) and other impermeable materials known in the art.
- the device can be assembled as follows. Gene construct formulation 20 is placed in first wall section 14 at its end opposite the end that is initially open. A "bilayer osmotic plug" composed of piston 24 and expansion agent 22 is prepared in a shape that will fit within second wall section 16. The piston 24 and expansion agent 22 are compressed into a tablet on a rotary bilayer tablet press. The bilayer osmotic plug is placed within the second wall section 16 and the assembly is placed over the end of the filled first housing so that piston 24 is adjacent to the gene construct formulation 20. When the device of the invention has the configuration shown in FIGs.
- the housing 32 may be prepared as a hollow cylinder that is closed at one end.
- the cylinder may be a water permeable material as described above and coated with an impermeable coating in the portion that contains the gene construct formulation 20.
- the plug 36 may be a water-swellable material.
- the device is assembled by preparing an osmotic plug as described above from the expansion agent 40 and the piston 42. This plug is placed into the closed end of the hollow cylinder, with the expansion agent 40 adjacent the closed end of the cylinder.
- the gene construct formulation is then placed into the housing 32 adjacent the piston 42.
- the plug 36 is then placed into the open end 34 of the housing 32.
- a delivery device for delivering a gene construct formulation according to the invention is prepared as follows.
- the osmotic engine portion of the device is a compressed bilayer tablet composed of a 150 mg polymeric osmotic formulation (expansion agent) and a 50 mg wax-based barrier (piston).
- the polymeric osmotic formulation has a composition of 60 wt% polyethylene oxide (Polyox® 303, Union Carbide), 29 wt% sodium chloride, 5 wt% polyacrylic acid (Carbomer® 934P, B.F. Goodrich), 5 wt% hydroxypropylmethylcellulose E-5, and 1 wt% ferric oxide.
- Polyox® 303 Union Carbide
- 29 wt% sodium chloride 5 wt% polyacrylic acid
- Carbomer® 934P Polyacrylic acid
- B.F. Goodrich 5 wt% hydroxypropylmethylcellulose E-5
- 1 wt% ferric oxide 1 wt% ferric oxide.
- each of the above components is screened through a 40 mesh screen, and the sized components are added to a mixing vessel in the appropriate proportions.
- the dry components are mixed thoroughly for 10 minutes; then, SDA 3A ethanol is slowly added while mixing continues until a wet mass is formed.
- the wax barrier has a composition of 95 wt% microcrystalline wax (MF-2JH Durawax®, Astor Wax Corp.) and 5 wt% gelatin (Type A, 275-300 bloom).
- MF-2JH Durawax® Astor Wax Corp.
- 5 wt% gelatin Type A, 275-300 bloom.
- each component is screened through a 40 mesh screen before being added in the correct weight ratio to a mixing vessel.
- the dry materials are mixed thoroughly for 10 minutes; then, purified water is slowly added to the mixture while stirring continues. After a wet mass forms, the mixture is passed through a 20 mesh screen, and the granules are oven-
- SUBSTTTUTE SHEET dried at 40°C for 24 hours. After the granules are dried, they are re-screened through a 20 mesh screen.
- the osmotic formulation and the wax barrier formulation are compressed in a hydraulic or rotary press into a cylindrical bilayer tablet.
- the osmotic face of the tablet is convex, to conform to the shape of the delivery device, while the barrier face of the tablet is flat. Tabletting is conducted to produce a clean, distinct interface between the two layers.
- the vessel portion (first wall section) of the device To prepare the vessel portion (first wall section) of the device, 70 wt% cellulose acetate 320 and 30 wt% polypropylene glycol are thoroughly mixed together and are then added to the hopper of a screw extruder. The polymeric mixture is heated at 127°C as it is extruded through the heated barrel of the extruder and into a mold for the vessel. The polymer mixture is allowed to cool after injection into the mold, after which the vessel is removed from the opened mold.
- the cap portion (second wall section) of the device is prepared in the same manner as the vessel, the composition of the cap being 70 wt% cellulose acetate 320 and 30 wt% polypropylene glycol.
- the heated polymeric mixture is injected into a mold for the cap and allowed to cool, and the finished cap is then ejected.
- the desired gene construct formulation is placed into a completed vessel by manual or automated fill mechanisms.
- the osmotic engine bilayer tablet is placed into a completed cap with the convex osmotic layer pointed into the closed end of the cap and the barrier layer exposed toward the cap opening.
- the open end of the filled vessel is fitted inside the open end of the cap, and the two pieces are compressed together until cap, osmotic bilayer tablet and vessel fit together tightly.
- a delivery device is prepared as in Example 1. The assembled device is then coated with approx. 20 mg of a methacrylic acid copolymer enteric coating (Eudragit® L 100-55, Rohm Pharma).
- a methacrylic acid copolymer enteric coating (Eudragit® L 100-55, Rohm Pharma).
- a delivery device containing an adenovirus vector formulation is prepared as follows.
- the E1 region of the adenovirus genome is deleted and replaced with the ⁇ 1-antitrypsin expression cassette as described in Crystal, PCT/US92/07029, which is incorporated herein by reference.
- This replication-defective virus is propagated in the human kidney cell line 293 which supplies the E1 products in trans. Virus is recovered after cells lysis, purified using cesium chloride gradients, and concentrated.
- the adenovirus gene construct is then incorporated into the delivery device described in Example 1.
- Delivery devices according to the present invention containing non ⁇ viral vector formulations are prepared follows.
- Liposomes are prepared by the dehydration-rehydration techniques described by Gregoriadis and Panagiotidi (Immunol. Lett. 1989, 20:237-240).
- Distearolyphosphatidylcholine, hydrogenated phosphatidylse ne and cholesterol in a molar ratio of 1 :1 :2 are dissolved in chloroform/methanol (9:1 v/v).
- the dried lipid film is rehydrated with the aqueous solution of gene construct Factor VIII expression plasmid as described in Eaton et al., Biochemistry 25, 8343-8347, which is incorporated by reference herein, with vortexing for 10 minutes at 50-55°C.
- SUBSTITUTE SHEET preparation is lyophilized. A portion of the preparation is rehydrated with 0.9% NaCl. The liposome/construct formulations, one in lyophilized form and one in rehydrated form are loaded into separate delivery devices as described in Example 1.
- each containing 500 mg of the adenovirus vector (AV) formulation are tested for release of the viral vector formulation using the USP paddle method (at 150 rpm).
- the devices are placed in 500 mL of pH 7 solution with 0.1% bovine albumin and stirred.
- the devices are observed to determine when the cap and drug vessel separate from each other, and the solution is tested for presence of AV to confirm the release time and the duration of release.
- the presence of virus can be determined by standard plaque forming assays in susceptible host cell lines.
- Each device will release its contents completely after 4 to 8 hours and over a short duration of time of less than half an hour.
- each containing 500 mg of the adenovirus vector formulation are tested to determine if transduction of the Gl epithelial cells has occurred.
- the device, with enteric coating as described in Example 2 is orally administered on Day 0.
- a booster inoculation is administered 2 weeks following initial dosing when the gene construct is intended to elicit an immunological response.
- Blood and salivary samples are collected subsequent to booster inoculation and serum IgG and salivary IgA levels determined by ELISA assay.
- a significant rise in serum IgG and/or IgA is indicative of effective transfection and generation of immunological response by the administered gene construct.
- SUBSTITUTE SHEET rise in levels of expressed peptide or protein in the serum is indicative of efficacious transfection and expression.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60978/96A AU6097896A (en) | 1995-06-07 | 1996-06-07 | Oral delivery of gene constructs |
JP9501704A JPH11507340A (en) | 1995-06-07 | 1996-06-07 | Oral delivery of gene constructs |
EP96918287A EP0831771A2 (en) | 1995-06-07 | 1996-06-07 | Oral delivery of gene constructs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47596195A | 1995-06-07 | 1995-06-07 | |
US08/475,961 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996040081A2 true WO1996040081A2 (en) | 1996-12-19 |
WO1996040081A3 WO1996040081A3 (en) | 1997-02-20 |
Family
ID=23889916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009371 WO1996040081A2 (en) | 1995-06-07 | 1996-06-07 | Oral delivery of gene constructs |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0831771A2 (en) |
JP (1) | JPH11507340A (en) |
KR (1) | KR19990022184A (en) |
AU (1) | AU6097896A (en) |
CA (1) | CA2221323A1 (en) |
WO (1) | WO1996040081A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0832266A1 (en) * | 1995-06-07 | 1998-04-01 | Yale University | Oral delivery of adeno-associated viral vectors |
WO1999030746A1 (en) * | 1997-12-12 | 1999-06-24 | Synoptik A/S | Container for timed release of substances |
WO2000035494A1 (en) * | 1998-12-14 | 2000-06-22 | Synoptik Holding A/S | A system for cleaning contact lenses |
EP1019030A1 (en) * | 1997-10-07 | 2000-07-19 | Port Systems, L.L.C. | Method for making a multi-stage drug delivery system |
US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
WO2002089855A1 (en) * | 2001-04-27 | 2002-11-14 | Auckland Uniservices Limited | Peroral transduction of hepatocytes in the treatment of disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003769A1 (en) * | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
WO1993019660A1 (en) * | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
-
1996
- 1996-06-07 WO PCT/US1996/009371 patent/WO1996040081A2/en not_active Application Discontinuation
- 1996-06-07 EP EP96918287A patent/EP0831771A2/en not_active Withdrawn
- 1996-06-07 KR KR1019970708663A patent/KR19990022184A/en not_active Application Discontinuation
- 1996-06-07 CA CA002221323A patent/CA2221323A1/en not_active Abandoned
- 1996-06-07 AU AU60978/96A patent/AU6097896A/en not_active Abandoned
- 1996-06-07 JP JP9501704A patent/JPH11507340A/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003769A1 (en) * | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
WO1993019660A1 (en) * | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0832266A1 (en) * | 1995-06-07 | 1998-04-01 | Yale University | Oral delivery of adeno-associated viral vectors |
EP0832266A4 (en) * | 1995-06-07 | 2000-06-28 | Univ Yale | Oral delivery of adeno-associated viral vectors |
US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US6258789B1 (en) | 1996-09-19 | 2001-07-10 | The Regents Of The University Of California | Delivery of gene products by intestinal cell expression |
US6831070B2 (en) | 1996-09-19 | 2004-12-14 | Regents Of The University Of California | Delivery of therapeutic gene products by intestinal cell expression |
EP1019030A1 (en) * | 1997-10-07 | 2000-07-19 | Port Systems, L.L.C. | Method for making a multi-stage drug delivery system |
EP1019030A4 (en) * | 1997-10-07 | 2006-04-12 | Port Systems L L C | Method for making a multi-stage drug delivery system |
WO1999030746A1 (en) * | 1997-12-12 | 1999-06-24 | Synoptik A/S | Container for timed release of substances |
US6382408B1 (en) | 1997-12-12 | 2002-05-07 | Synoptik A/S | Container for timed release of substances |
WO2000035494A1 (en) * | 1998-12-14 | 2000-06-22 | Synoptik Holding A/S | A system for cleaning contact lenses |
WO2002089855A1 (en) * | 2001-04-27 | 2002-11-14 | Auckland Uniservices Limited | Peroral transduction of hepatocytes in the treatment of disease |
Also Published As
Publication number | Publication date |
---|---|
WO1996040081A3 (en) | 1997-02-20 |
EP0831771A2 (en) | 1998-04-01 |
CA2221323A1 (en) | 1996-12-19 |
JPH11507340A (en) | 1999-06-29 |
KR19990022184A (en) | 1999-03-25 |
AU6097896A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5443459A (en) | Osmotic device for delayed delivery of agent | |
JP3307929B2 (en) | Osmotic devices for delayed administration of drugs | |
EP2642978B1 (en) | Immunomodulatory compositions comprising hydralazine and cyclosporine a for the treatment of gastrointestinal disorders | |
EP0768867B1 (en) | Dosage form for administering drug in liquid formulation | |
MXPA01005346A (en) | An oral formulation for gastrointestinal drug delivery. | |
JP2010502759A (en) | Pharmaceutical composition for oral or rectal administration of protein substances | |
WO2004026453A2 (en) | Microcapsules and methods of use | |
EP1090645A2 (en) | Oral delivery of chemically modified proteins | |
JPH07504401A (en) | Osmotic device with delayed activation of drug administration | |
US20240239856A1 (en) | Compositions, formulations and interleukin production and purification | |
CN102552919A (en) | Administration combination and preparation and use methods thereof | |
CN102100912B (en) | Administration composition and preparation method and using method thereof | |
US20050031544A1 (en) | Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases | |
WO1996040081A2 (en) | Oral delivery of gene constructs | |
AU1820999A (en) | Grafted copolymers as gene carriers | |
CN102335431B (en) | A kind of administration composition and preparation and application thereof | |
EP0844004B1 (en) | Collagen containing gene preparations | |
KR19990021985A (en) | Osmotic devices with high drug loading and delayed activation of drug delivery | |
JP2005508875A (en) | Peptides for use as translocation factors | |
KR100428273B1 (en) | Osmotic devices with delayed activation of drug delivery and complete drug release function | |
CN1187118A (en) | Oral delivery of gene constructs | |
WO2000016784A1 (en) | Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin | |
Mackay | Delivery of therapeutic peptides and proteins | |
Truong-Le | Synthesis, gene transfer properties, and delivery of genetic vaccines using the DNA-gelatin nanospheres | |
NZ268251A (en) | Sustained release dosage form for delivering a drug in non-aqueous liquid form through an exit hole via a "push" composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194471.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2221323 Country of ref document: CA Ref document number: 2221323 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970708663 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996918287 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1997 501704 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1996918287 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970708663 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996918287 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970708663 Country of ref document: KR |